If you have been reading about research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-10. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
By the abdication of his uncle Ferdinand and the renunciation of his mild-mannered father, Franz Karl, Franz Joseph succeeded as Emperor of Austria at Olmütz on 2 December 1848. This was the first time at which he became known by his first and second given names together. The name "Franz Joseph" was chosen to bring back memories of the new Emperor's great-granduncle, Emperor Joseph II (Holy Roman Emperor from 1765 to 1790), remembered as a modernising reformer. Under the guidance of the new prime minister, Prince Felix of Schwarzenberg, the new emperor initially pursued a cautious course, granting a constitution in March 1849. At the same time, a military campaign was deemed necessary against the Hungarians, who had rebelled against Habsburg central authority in the name of their ancient constitution. Franz Joseph also almost immediately faced a renewal of the fighting in Italy, with King Charles Albert of Sardinia taking advantage of setbacks in Hungary to resume the war in March 1849.
==== MeSH D12.776.624.664.520 – oncogene proteins, viral ==== MeSH D12.776.624.664.520.045 – adenovirus early proteins MeSH D12.776.624.664.520.045.050 – adenovirus E1 proteins MeSH D12.776.624.664.520.045.050.100 – adenovirus E1A proteins MeSH D12.776.624.664.520.045.050.110 – adenovirus E1B proteins MeSH D12.776.624.664.520.045.060 – adenovirus e2 proteins MeSH D12.776.624.664.520.045.070 – adenovirus e3 proteins MeSH D12.776.624.664.520.045.080 – adenovirus e4 proteins MeSH D12.776.624.664.520.090 – antigens, polyomavirus transforming MeSH D12.776.624.664.520.420 – papillomavirus e7 proteins MeSH D12.776.624.664.520.750 – retroviridae proteins, oncogenic MeSH D12.776.624.664.520.750.320 – fusion proteins, gag-onc MeSH D12.776.624.664.520.750.320.700 – oncogene protein p65(gag-jun) MeSH D12.776.624.664.520.750.470 – gene products, rex MeSH D12.776.624.664.520.750.480 – gene products, tax MeSH D12.776.624.664.520.750.650 – oncogene protein gp140(v-fms) MeSH D12.776.624.664.520.750.710 – oncogene protein p21(ras) MeSH D12.776.624.664.520.750.750 – oncogene protein p55(v-myc) MeSH D12.776.624.664.520.750.760 – oncogene protein pp60(v-src) MeSH D12.776.624.664.520.750.788 – oncogene protein v-akt MeSH D12.776.624.664.520.750.817 – oncogene protein v-cbl MeSH D12.776.624.664.520.750.846 – oncogene protein v-crk MeSH D12.776.624.664.520.750.860 – oncogene protein v-maf MeSH D12.776.624.664.520.750.875 – oncogene proteins v-abl MeSH D12.776.624.664.520.750.882 – oncogene proteins v-erba MeSH D12.776.624.664.520.750.883 – oncogene proteins v-erbb MeSH D12.776.624.664.520.750.887 – oncogene proteins v-fos MeSH D12.776.624.664.520.750.900 – oncogene proteins v-mos MeSH D12.776.624.664.520.750.903 – oncogene proteins v-myb MeSH D12.776.624.664.520.750.920 – oncogene proteins v-raf MeSH D12.776.624.664.520.750.925 – oncogene proteins v-rel MeSH D12.776.624.664.520.750.935 – oncogene proteins v-sis
People already stabilized on other opioids who have persistent swallowing problems and cannot tolerate other parenteral routes such as subcutaneous administration. People with moderate to severe kidney failure. Troublesome side effects of oral morphine, hydromorphone, or oxycodone. When using the transdermal patch, patients must be careful to minimize or avoid external heat sources (direct sunlight, heating pads, etc.), which can trigger the release and absorption of too much medication and cause potentially deadly complications.
After a dispute with Yale over his forced retirement and the rights to his invention of electrospray ionization, Fenn moved to Richmond, Virginia to join Virginia Commonwealth University's (VCU) department of chemistry as an analytical chemistry professor. VCU established an engineering department in the late 1990s, and Fenn held a joint professorship between the two departments until his death. Even in his 80s, Fenn enjoyed the opportunity to be in the lab doing research, saying, "I like to mingle and exchange with the young people. It gets me out from underfoot at home."
Sources: en.wikipedia.org
Initially, Mexican participation in the war was limited to the military defense of the coasts of Baja California, but the Allied powers pressed for Mexico to send a symbolic force to the battlefield. In 1943, due to the military situation in Europe, the Mexican government began to reconsider its refusal to participate in the war with Mexican troops there. By that time, the Allies were already on the offensive on all fronts and the possibility of a German or Japanese attack on the North American continent seemed increasingly remote. Therefore, Mexico decided to send to the war front a symbolic force to fight under the Mexican flag, providing that it would be an air force contingent in the Pacific campaign. Thus, in 1944, the 201st Squadron arrived in the United States for aviation training. A year later, in 1945, the Mexican squadron (known as the Aztec Eagles) was ready for battle; this squadron of fighter planes participated directly in the Philippines campaign alongside the United States Air Force and Royal Australian Air Force. The 201st Squadron arrived at Majors Field in Greenville, Texas on November 30, 1944. There, the pilots received advanced training in combat air tactics, formation flying and gunnery. The men were honored with graduation ceremonies on February 20, 1945, and the squadron was presented with its battle flag. This marked the first time that Mexican troops were trained for overseas combat. In charge of the group was Colonel Antonio Cárdenas Rodríguez, and Captain First Class Radamés Gaxiola Andrade was named squadron commander.
Founded in 1896 by Fritz Hoffmann-La Roche, the company was known early on for producing various vitamin preparations and derivatives. In 1934, it became the first company to mass-produce synthetic vitamin C, under the brand name Redoxon. During the Second World War, Roche collaborated with the Nazi regime in Germany and used forced labour in its German and Polish-based factories. It also moved all its Jewish employees to the United States to save them from Nazi attention. In 1957, Hoffmann-La Roche introduced the class of tranquilizers known as benzodiazepines (with Valium and Rohypnol being the best known members). It manufactures and sells several cancer drugs and is a leader in this field. In 1956, the first antidepressant, iproniazid, was accidentally created during an experiment while synthesizing isoniazid. Originally, it had been intended to create a more efficient drug at combatting tuberculosis. Iproniazid, however, was revealed to have its own benefits; some people felt it made them feel happier. It was withdrawn from the market in the early 1960s due to toxic side-effects. In 1976, an accident at a chemical factory in Seveso, Italy, owned by a subsidiary of Roche, caused a large dioxin contamination. In 1982, the United States arm of the company acquired Biomedical Reference Laboratories for US$163.5 million. That company dated from the late 1960s, and was located in Burlington, North Carolina. That year Hoffmann-La Roche then merged it with all of its laboratories, and incorporated the merged company as Roche Biomedical Laboratories, Inc. in Burlington.
== Mechanism of action == Phalloidin binds F-actin, preventing its depolymerization and poisoning the cell. Phalloidin binds specifically at the interface between F-actin subunits, locking adjacent subunits together. Phalloidin, a bicyclic heptapeptide, binds to actin filaments much more tightly than to actin monomers, leading to a decrease in the rate constant for the dissociation of actin subunits from filament ends, which essentially stabilizes actin filaments through the prevention of filament depolymerization. Moreover, phalloidin is found to inhibit the ATP hydrolysis activity of F-actin. Thus, phalloidin traps actin monomers in a conformation distinct from G-actin and it stabilizes the structure of F-actin by greatly reducing the rate constant for monomer dissociation, an event associated with the trapping of ADP. Overall, phalloidin is found to react stoichiometrically with actin, strongly promote actin polymerization, and stabilize actin polymers. Phalloidin functions differently at various concentrations in cells. When introduced into the cytoplasm at low concentrations, phalloidin recruits the less polymerized forms of cytoplasmic actin as well as filamin into stable "islands" of aggregated actin polymers, yet it does not interfere with stress fibers, i.e. thick bundles of microfilaments. Wehland et al. also notes that at higher concentrations, phalloidin induces cellular contraction.
=== Selective norepinephrine reuptake inhibitors === Noradrenergic neurons are located in two major regions in the brain, the locus coeruleus and lateral tegmental. With administration of SNRIs, neuronal activity in the locus coeruleus is induced because of increased concentration of norepinephrine in the synaptic cleft. This results in activation of α2 adrenergic receptors, as discussed previously. Assays have shown that SNRIs have insignificant penchant for mACh, α1 and α2 adrenergic, or H1 receptors.
The drugs characteristics, including its pKa. Redistribution through an organism's tissues: Some drugs are distributed rapidly in some tissues until they reach equilibrium with the plasma concentration. However, other tissues with a slower rate of distribution will continue to absorb the drug from the plasma over a longer period. This will mean that the drug concentration in the first tissue will be greater than the plasma concentration and the drug will move from the tissue back into the plasma. This phenomenon will continue until the drug has reached equilibrium over the whole organism. The most sensitive tissue will therefore experience two different drug concentrations: an initial higher concentration and a later lower concentration as a consequence of tissue redistribution. Concentration differential between tissues. Exchange surface. Presence of natural barriers. These are obstacles to a drug's diffusion similar to those encountered during its absorption. The most interesting are: Capillary bed permeability, which varies between tissues. Blood-brain barrier: this is located between the blood plasma in the cerebral blood vessels and the brain's extracellular space. The presence of this barrier makes it hard for a drug to reach the brain. Placental barrier: this prevents high concentrations of a potentially toxic drug from reaching the foetus.
Sources: en.wikipedia.org
=== Testing on children in New York City === The New York Psychiatric Institute, associated with Columbia University, the Research Foundation of the City University of New York, and Mount Sinai Medical Center tested fenfluramine intravenously on more than 100 Black and Hispanic boys between the ages of 6 and 10, with delinquent older brothers, to test the theory that delinquent behavior could be predicted by serotonin levels. These studies were conducted before the drug was pulled from the market in September 1997. In 1998, CNN reported that these organizations were under "evaluation" by the Office for Protection from Research Risks, an arm of the National Institutes of Health. An article in Nature reports that these tests were published as a study in Archives of General Psychiatry in 1997 and that "The New York trial, funded largely by the Lowenstein Foundation, with some support from the National Institute of Mental Health, was halted in 1995, two years before the drug was withdrawn." In 1999, The New York Times reported that the Mount Sinai School of Medicine and the Research Foundation of the City University of New York were officially faulted by federal research-ethics officials for conducting these tests. The article reports that the yearlong investigation found no misconduct by the New York State Psychiatric Institute for these tests. This article reports the number of children involved in the study as 150 and states that none were harmed.
2010: Marcia McNutt became the first female director of the United States Geological Survey. 2011: Kazakhstani neuroscience student and computer hacker Alexandra Elbakyan launched Sci-Hub, a website that provides users with pirated copies of scholarly scientific papers. Within five years, Sci-Hub grew to contain 60 million papers and recorded over 42 million annual downloads by users. Elbakyan was finally sued by major academic publishing company Elsevier, and Sci-Hub was subsequently taken down, but it reappeared under different domain names. 2011: Taiwanese-American astrophysicist Chung-Pei Ma led a team of scientists in discovering two of the largest black holes ever observed. 2012: Israeli-American computer scientist and cryptographer Shafi Goldwasser won the Turing award for her contributions to cryptography and complexity theory. 2013: Canadian-British genetic specialist Turi King identified the 500-year-old skeletal remains of King Richard III. 2013: Kenyan ichthyologist Dorothy Wanja Nyingi published the first guide to freshwater fish species of Kenya. 2013: Canadian teenagers Miranda Wang and Jeanny Yao jointly identify a bacteria in British Columbia's Fraser River that breaks down phthalates. 2014: Norwegian psychologist and neuroscientist May-Britt Moser received the Nobel Prize in Physiology or Medicine, shared with Edvard Moser and John O'Keefe, "for their discoveries of cells that constitute a positioning system in the brain".
Most cases of SCID are due to mutations in the IL2RG gene encoding the common gamma chain (γc) (CD132), a protein that is shared by the receptors for interleukins IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21. These interleukins and their receptors are involved in the development and differentiation of T and B cells. Because the common gamma chain is shared by many interleukin receptors, mutations that result in a non-functional common gamma chain cause widespread defects in interleukin signalling. The result is a near complete failure of the immune system to develop and function, with low or absent T cells and NK cells and non-functional B cells.The common gamma chain is encoded by the gene IL-2 receptor gamma, or IL-2Rγ, which is located on the X-chromosome. For this reason, immunodeficiency caused by mutations in IL-2Rγ is known as X-linked severe combined immunodeficiency. The condition is inherited in an X-linked recessive pattern.
Paracetamol poisoning, also known as acetaminophen poisoning, is caused by excessive use of the medication paracetamol (acetaminophen). Most people have few or non-specific symptoms in the first 24 hours following overdose. These symptoms include feeling tired, abdominal pain, or nausea. This is typically followed by absence of symptoms for a couple of days, after which yellowish skin, blood clotting problems, and confusion occurs as a result of liver failure. Additional complications may include kidney failure, pancreatitis, low blood sugar, and lactic acidosis. If death does not occur, people tend to recover fully over a couple of weeks. Without treatment, death from toxicity occurs 4 to 18 days later. Paracetamol poisoning can occur accidentally or as a suicide attempt. Risk factors for toxicity include alcoholism, malnutrition, and the taking of certain other hepatotoxic medications. Liver damage results not from paracetamol itself, but from one of its metabolites, N-acetyl-p-benzoquinone imine (NAPQI). NAPQI decreases the liver's glutathione and directly damages cells in the liver. Diagnosis is based on the blood level of paracetamol at specific times after the medication was taken. These values are often plotted on the Rumack-Matthew nomogram to determine level of concern. Treatment may include activated charcoal if the person seeks medical help soon after the overdose. Attempting to force the person to vomit is not recommended. If there is a potential for toxicity, the antidote acetylcysteine is recommended. The medication is generally given for at least 24 hours.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.